Statin safety: a systematic review

Area of Science:

• Pharmacovigilance and Drug Safety
• Cardiovascular Pharmacology
• Clinical Epidemiology

Background:

• 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, commonly known as statins, are widely prescribed lipid-lowering medications.
• Understanding the incidence and characteristics of their adverse effects is crucial for patient safety and clinical decision-making.

Purpose of the Study:

• To systematically review the incidence and characteristics of adverse effects associated with statin therapy.
• To evaluate specific risks such as rhabdomyolysis, myopathy, liver disease, renal dysfunction, peripheral neuropathy, and cognitive changes.

Main Methods:

• Systematic review encompassing cohort studies, randomized trials, regulatory authority notifications, and published case reports.
• Analysis of incidence rates for various adverse events, stratified by statin type, concomitant medications, and patient populations.

Main Results:

• Rhabdomyolysis incidence was 3.4 per 100,000 person-years, with a 10% case fatality rate, significantly higher when combined with gemfibrozil.
• Myopathy incidence was 11 per 100,000 person-years; statins showed fewer hepatobiliary disorders than placebo.
• Peripheral neuropathy risk was low (12 per 100,000 person-years), with no observed adverse effects on renal function or cognitive abilities in elderly patients.

Conclusions:

• Statin therapy is associated with a low incidence of serious adverse effects, but risks are elevated with specific drug combinations (e.g., gemfibrozil, CYP3A4 inhibitors).
• Statins generally demonstrate a favorable safety profile regarding liver, kidney, and cognitive function.
• Continued pharmacovigilance is essential to monitor and manage potential adverse events associated with statin use.